SCHEMBL4740446

SCHEMBL4740446

Nc1onc2c(F)ccc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 14/20 0.68
KIT P10721 8/20 0.68
FLT3 P36888 8/20 0.68
IKBKE Q14164 1/20 0.62
CSF1R P07333 4/20 0.61
FLT1 P17948 4/20 0.61
SRC P12931 3/20 0.61
FLT4 P35916 3/20 0.61
ABL1 P00519 3/20 0.61
LCK P06239 3/20 0.61
FYN P06241 3/20 0.61
LYN P07948 3/20 0.61
BLK P51451 3/20 0.61
TEK Q02763 3/20 0.60
GSK3B P49841 3/20 0.60
PDGFRB P09619 3/20 0.60
RIPK1 Q13546 2/20 0.60
GSK3A P49840 2/20 0.60
EGFR P00533 1/20 0.60
PDGFRA P16234 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4738177 0.93 KDR (0.64) KDRKITFLT3IKBKECSF1R
SCHEMBL1383935 0.90 KDR (0.62) KDRKITFLT3IKBKECSF1R
SCHEMBL5253491 0.90 KDR (0.64) KDRKITFLT3IKBKECSF1R
SCHEMBL4739162 0.89 KDR (0.66) KDRKITFLT3CSF1RFLT1
SCHEMBL1384952 0.87 KDR (0.74) KDRKITFLT3IKBKECSF1R
SCHEMBL421220 0.86 KDR (0.77) KDRKITFLT3IKBKECSF1R
SCHEMBL4740129 0.86 KDR (0.75) KDRKITFLT3CSF1RFLT1
SCHEMBL1379590 0.85 KDR (0.67) KDRKITFLT3CSF1RFLT1
SCHEMBL1381921 0.85 IKBKE (0.82) KDRKITFLT3IKBKECSF1R
SCHEMBL423371 0.83 KDR (0.80) KDRKITFLT3IKBKECSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO disclosed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP disclosed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO disclosed